Original Article
Biennial Endoscopic Surveillance of Gastrointestinal Metaplasia and Its Subtypes Reduces Gastric Cancer Mortality and Is Cost-Effective in a Markov State Transition Model
Abstract
Objectives: Gastric cancer in the United States has a low survival rate mainly because of the late stage of diagnosis. Furthermore, there are no well-established guidelines concerning screening and surveillance even for higher risk patients such as those with nondysplastic noncardia gastrointestinal metaplasia (GIM), and thus they are not routinely performed. This study was designed to provide new evidence-based data that can be used to support the implementation of biennial surveillance guidelines in individuals with nondysplastic noncardia GIM. This practice can help detect early malignant lesions, thereby decreasing morbidity and mortality. We evaluated the cost-effectiveness of surveillance endoscopies for noncardia gastric cancer in populations with two different pathological diagnoses: mixed GIM and incomplete GIM (iGIM).Methods: Markov state transition models were developed using a cohort simulation of 1000 hypothetical patients. Analysis was conducted for both mixed and iGIM. Quality-adjusted life-years and transition probabilities were derived from the published medical literature. Costs associated with endoscopy, cancer care, and surgery were based on Medicare reimbursement. A willingness-to-pay threshold of $100,000 per quality-adjusted life-year was used to determine cost-effectiveness.
Results: Our study determined that it is significantly cost-effective to perform biennial endoscopy surveillance in patients who have been incidentally found to have noncardia mixed GIM, with a cost savings of $5783.84 per person, and in those with iGIM, with a cost savings of $8093.08 per person.
Conclusions: Biennial endoscopy surveillance should be considered in all individuals found to have mixed or incomplete noncardia GIM on endoscopy. Furthermore, screening specifically for iGIM after differentiating between the two groups can lead to further cost savings. As such, we recommend that pathologists routinely differentiate between the two and recommend robust routine surveillance of iGIM.
Posted in: Gastroenterology53
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Choi I, Kim C, Lee J, et al. Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med 2020;382:427–436.
2. Khoder G, Muhammad JS, Mahmoud I, et al. Prevalence of Helicobacter pylori and its associated factors among healthy asymptomatic residents in the United Arab Emirates. Pathogens 2019;8:44.
3. Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 2000;22:283–297.
4. Everhart JE, Kruszon-Moran D, Perez-Perez GI, et al. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis 2000;181:1359–1363.
5. Forman D, Newell DG, Fullerton F. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ 1991;302:1302–1305.
6. Parsonnet J, Friedman GD, Vandersteen DP. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127–1131.
7. Nomura A, Stemmermann GN, Chyou PH. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991;325:1132–1136.
8. Moss SF. The clinical evidence linking Helicobacter pylori to gastric cancer. Cell Molec Gastroenterol Hepatol 2016;3:183–191.
9. Raza M, Bhatt H. Atrophic gastritis. https://pubmed.ncbi.nlm.nih.gov/33085422/. Updated July 25, 2022. Accessed September 12, 2023.
10. Chen HN, Wang Z, Li X, et al. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer 2016;19:166–175.
11. Rokkas T, Rokka A, Portincasa P. A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Ann Gastroenterol 2017;30:414–423.
12. Bizzaro N, Antico A, Villalta D. Autoimmunity and gastric cancer. Int J Mol Sci 2018;26;19:377.
13. Rustgi SD, Bijlani P, Shah SC. Autoimmune gastritis, with or without pernicious anemia: epidemiology, risk factors, and clinical management. Therap Adv Gastroenterol 2021;14:17562848211038771.
14. Elsborg L, Mosbech J. Pernicious anaemia as a risk factor in gastric cancer. Acta Med Scand 1979;206:315–318.
15. Saumoy M, Schneider Y, Shen N, et al. Cost effectiveness of gastric cancer screening according to race and ethnicity. Gastroenterology 2018;155: 648–660.
16. Ansari S, Yamaoka Y. Survival of Helicobacter pylori in gastric acidic territory. Helicobacter 2017;22:10.1111/hel.12386.
17. Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy 2019;51:365–388.
18. Gupta S, Li D, El Serag HB, et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology 2020;158: 693–702.
19. Shah SC, Piazuelo MB, Kuipers EJ, et al. AGA clinical practice update on the diagnosis and management of atrophic gastritis: expert review. Gastroenterology 2021;161:1325–1332.e7.
20. Correa P, Piazuelo M. The gastric precancerous cascade. J Dig Dis 2011;13:2–9.
21. Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol 2010;105:493–498.
22. Gupta N, Bansal A, Wani SB, et al. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis. Gastrointest Endosc 2011; 74:610–624.
23. Yeh JM, Hur C, Ward Z, et al. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut 2016;65:563–574.
24. Solanki S, Chakinala RC, Haq KF, et al. Inpatient burden of gastric cancer in the United States. Ann Transl Med 2019;7:772.
25. Lee J, Zhu F, Srivastava S, et al. Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicenter cohort study (GCEP). Gut 2022;71:854–863.
26. Pittayanon R, Rerknimitir R, Klaikaew N, et al. The risk of gastric cancer in patients with gastric intestinal metaplasia in 5-year follow-up. Aliment Pharmacol Therap 2017;46:40–45.
27. Quach DT, Hiyama T, Gotoda T. Identifying high-risk individuals for gastric cancer surveillance from western and eastern perspectives: lessons to learn and possibility to develop an integrated approach for daily practice. World J Gastroenterol 2019;25:3546–3562.
28. de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008;134:945–952.
29. Akbari M, Tabrizi R, Kardeh S, et al.. Gastric cancer in patients with gastric atrophy and intestinal metaplasia: a systematic review and meta-analysis. PLoS ONE 2019;14:e0219865.
30. International Agency for Research on Cancer. Cancer today. Estimated age-standardized incidence rates (world) in 2020, world, both sexes, all ages (excl. NMSC). https://gco.iarc.fr/today/online-analysis-multi-bars?v=2020. Published 2020. Accessed September 12, 2023.
31. Hamashima C, Ogoshi K, Narisawa R, et al.. Impact of endoscopic screening on mortality reduction from gastric cancer. World J Gastroenterol 2015;21:2460–2466.
32. Kim J, Sun CL, Mailey B, et al. Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann Oncol 2010;21:152–160.
33. Lee T, Wang R, Lee Y, et al. The incidence of gastric adenocarcinoma among patients with gastric intestinal metaplasia. J Clin Gastroenterol 2016;50:532–537.
34. Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori–infected persons, United States. Emerg Infect Dis 2004;10:1088–1094.
35. Liu KS, Wong IO, Leung WK. Helicobacter pylori associated gastric intestinal metaplasia: treatment and surveillance. World J Gastroenterol 2016;22:1311–1320.
36. Olmez S, Aslan M, Erten R, et al. The prevalence of gastric intestinal metaplasia and distribution of Helicobacter pylori infection, atrophy, dysplasia, and cancer in its subtypes. Gastroenterol Res Pract 2015;2015:434039.
37. Craanen ME, Dekker W, Blok P, et al. Intestinal metaplasia and H. pylori: an endoscopic bioptic study of the gastric antrum. Gut 1992;33:16–20.
38. Zhang X, Li M, Chen S, et al. Endoscopic screening in Asian countries is associated with reduced gastric cancer mortality: a meta-analysis and systematic review. Gastroenterology 2018;155:347–354.e9.
39. Dicken BJ, Bigam DL, Cass C, et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005;241:27–39.
40. Karve S, Lorenzo M, Liepa AM, et al. Treatment patterns, costs, and survival among Medicare-enrolled elderly patients diagnosed with advanced stage gastric cancer: analysis of a linked population-based cancer registry and administrative claims database. J Gastric Cancer 2015;15:87–104.
41. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol 2019;14:26–38.
42. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008;100:630–641.
43. Selby LV, Gennarelli RL, Schnorr GC, et al. Association of hospital costs with complications following total gastrectomy for gastric adenocarcinoma. JAMA Surg 2017;152:953–958.
44. Mariotto AB, Enewold L, Zhao J, et al. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomarkers Prev 2020;29:1304–1312.
45. Tufts University Medical Center. CEA registry. http://healtheconomics.tuftsmedicalcenter.org/cear2n/search/search.aspx. Accessed January 1, 2022.
46. Centers for Medicare & Medicaid Services. Physician fee schedule. https://www.cms.gov/medicare/physician-fee-schedule/search/license-agreement?destination=/medicare/physician-fee-schedule/search%3FY%3d0%26#x0026;T=0&HT=0&CT=3&H1=91065&M=5. Accessed January 1, 2022.
47. Shaukat A, Kahi CJ, Burke CA, et al. ACG clinical guidelines: colorectal cancer screening. Am J Gastroenterol 2021;116:458–479.
48. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry 2005;187:106–108.
49. Areia M, Spaander M, Kuipers E, et al. Endoscopic screening for gastric cancer: a cost-utility analysis for countries with an intermediate gastric cancer risk. United European Gastroenterol J 2018;6:192–202.
50. Doubeni C, Corley D, Quinn V, et al. Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large communitybased study. Gut 2018;67:291–298.
51. Shah SC, Gawron AJ, Mustafa R, et al. Histologic subtyping of gastric intestinal metaplasia: overview and considerations for clinical practice. Gastroenterology 2020;158:745–750.
52. Yue H, Shan L, Bin L. The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysis. Gastric Cancer 2018;21:579–587.
53. Draganov PV, Aihara H, Karasik MS, et al. Endoscopic submucosal dissection in North America: a large prospective multicenter study. Gastroenterology 2021;160:2317–2327.e2.
54. Yang D, Wagh MS, Draganov PV. The status of training in new technologies in advanced endoscopy: from defining competence to credentialing and privileging. Gastrointest Endosc 2020;92:1016–1025.
